DFX Intelligence
Venture Capital Intelligence
Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.
Firms / Epsilon Health Investors, LLC
Epsilon Health Investors, LLC
Syndicate platformWashington Dc, DCepsilonhi.comSEC venture capital fund adviserfundraising evidence
name or self-description says syndicate platform
Importance
30
moderate
Active deployment
90
high
Emerging
0
low
Completeness
69
high
Freshness
100
high
Research priority
27
moderate
Identity and regulatory footprint
- Headquarters
- Washington Dc, DCadviserinfo.sec.gov
- Office address
- 1227 25TH STREET, NW, SUITE 700 OFFICE 628, Washington Dc, DC, 20037adviserinfo.sec.gov
- Business phone
- 646-256-0809adviserinfo.sec.gov
- Website
- http://www.epsilonhi.com
- SEC adviser type
- exempt reporting adviseradviserinfo.sec.gov
- SEC exemption claimed
- venture capital fund adviseradviserinfo.sec.govItem 2.B(1): advises solely venture capital funds
- Latest Form ADV
- Mar 26, 2026
- Private funds reported
- 5 (5 venture capital funds)adviserinfo.sec.gov
- Private fund gross assets
- $43.2Madviserinfo.sec.govreported GAV of the funds, the adviser's own number; not fund size, not dry powder
- business email
- partners@epsilonhi.comepsilonhi.compublished by the subject
- business phone
- 646-256-0809adviserinfo.sec.govpublished by the subject
Stated thesis versus observed behaviour
26 observed deals
Stated (the firm’s website)
- Sectors
- ai, healthcare, consumer, cybersecurity, media
- Stages
- seed, series b
- Geography
- boston, chicago, los angeles, new york, washington, dc
- Check size
- not stated; DFX does not estimate checks from round sizes
- Self-described
- syndicate platform
Observed (from deals on record)
Stage at participation: no observed deals yet
Stage at first entry: no observed deals yet
Sectors
unknown 96%Other Technology 4%
lead rate n/afollow-on rate n/anew logos, 12 months 26
Funds and vehicles
6 reported
| Vehicle | Type | Vintage | Lifecycle | Reported GAV | Owners | Form D sold | Latest Form D |
|---|---|---|---|---|---|---|---|
| Epsilon Spv IV, L.P. | SPV or co-invest vehicle | 2026 form d first sale | Newly closed | unknown | unknown | $3.7M of $3.7M | May 18, 2026 |
| Epsilon Spv IV, L.P. | SPV or co-invest vehicle | 2024 adv first reported | Early deployment | $525,954 Mar 28, 2024 | 2 | unknown | unknown |
| Epsilon Healthcare Innovation Fund II, LP | Fund | 2022 form d first sale | Fundraising | $12.5M Mar 28, 2024 | 17 | $17.6M of $50.0M | Oct 31, 2025 |
| Epsilon Healthcare Opportunites Fund, LP | Opportunity fund | 2021 form d first sale | Mature | $15.4M Mar 28, 2024 | 20 | $11.7M of $11.7M | Sep 27, 2021 |
| Epsilon Spv III, L.P. | SPV or co-invest vehicle | 2021 form d first sale | Mature | $3.0M Mar 28, 2024 | 9 | $2.1M of $2.1M | Dec 1, 2021 |
| Epsilon Spv I, L.P. | SPV or co-invest vehicle | 2020 form d first sale | Mature | $3.5M Mar 28, 2024 | 4 | $900,000 of $900,000 | Feb 19, 2020 |
GAV is the gross asset value the adviser reported on Form ADV for the vehicle, never the fund’s committed size and never dry powder. Form D sold is the amount sold as of the latest filing, never a final close.
Investment team
17 current, 0 departed
Andrew Lutes
AssociateAssociate
Fran Green
Board or advisoryAdvisor
Jeffrey Hillis
Board or advisoryAdvisor
Richard P. Burke
Board or advisoryAdvisor
Ted Kennedy Jr.
Board or advisoryAdvisor
Teri Fontenot
Board or advisoryAdvisor
William A. Keyes IV, PhD.
Board or advisoryAdvisor
Greg Epstein
General partnerGeneral Partner, Co-Founder
Steven Epstein
General partnerGeneral Partner, Co-Founder
Gregory H Epstein
Managing partnerManaging Member · since Jun 1, 2016
Steven B Epstein
Managing partnerManaging Member · since Jun 1, 2016
David Hillis
PartnerExecutive Partner
David Pitts
PartnerExecutive Partner
Leslie Norwalk
PartnerExecutive Partner
Steve Brady
PartnerPartner
Taylor Whitman
PartnerPartner
Kaitlynne Brock
Platform and operationsFinance Director
Investments on record
26 edges, 26 companies, 0 partner-attributed
“This investor” is the amount disclosed for this investor alone; it is unknown unless a source said it. The round size is the whole round.
Co-investors
18 relationships from shared deals, counted for the whole firm
TAU Ventures, LLC 2 shared · recurringHealth2047 Capital Partners Management, LLC 1 shared · one timeIA Capital Group, Inc. 1 shared · one timeModerne Capital, LP 1 shared · one timeU.S. Venture Partners 1 shared · one timeMercato 1 shared · one timeFlare Capital Management Company, LLC 1 shared · one timeDCVC 1 shared · one timeFrist Cressey Ventures Management, LLC 1 shared · one timeSpark Growth Ventures 1 shared · one timeRHO Capital Partners 1 shared · one timeKingsbridge Wealth Management: A Multi-Family Office 1 shared · one timeAlleycorp Advisers, LLC 1 shared · one timeThree-Sixty Health Venture Partners, LLC 1 shared · one timeLong River Capital Management II LLC 1 shared · one timeGreat Oaks Management Company LLC 1 shared · one timeLifeforce Capital Management, LLC 1 shared · one timeDreamit Ventures 1 shared · one time
Limited partners
0 disclosed
No LP commitment on record. An LP edge needs a public disclosure with a quote: a pension report (see Limited partners for the plans read), a fund announcement naming the LP, or a Form ADV owner. The fund page carries the LP’s reported performance.
Timeline
9 dated events
- Sep 16, 2026KODE Health no longer listed on Epsilon Health Investors, LLC's portfolio pageRemoved from portfolio pagePortfolioInferenceKODE HealthVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026Bayesian no longer listed on Epsilon Health Investors, LLC's portfolio pageRemoved from portfolio pagePortfolioInferenceBayesianVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 14, 2026Epsilon Health Investors, LLC: MICRO_VC -> SYNDICATE_PLATFORM (name or self-description says syndicate platform)Classification changedClassificationInferenceno URL
- Mar 28, 2024Epsilon Spv IV, L.P. first reported on Form ADV by Epsilon Health Investors, LLC (Venture Capital Fund), GAV $525,954Fund first reported on Form ADVFundsFactEpsilon Spv IV, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2023Epsilon Health Investors, LLC first filed Form ADV (ERA, venture capital fund adviser exemption)First SEC adviser filingOrganizationFactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2023Epsilon Healthcare Opportunites Fund, LP first reported on Form ADV by Epsilon Health Investors, LLC (Venture Capital Fund), GAV $16,296,807Fund first reported on Form ADVFundsFactEpsilon Healthcare Opportunites Fund, LPSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2023Epsilon Healthcare Innovation Fund II, LP first reported on Form ADV by Epsilon Health Investors, LLC (Venture Capital Fund), GAV $8,850,000Fund first reported on Form ADVFundsFactEpsilon Healthcare Innovation Fund II, LPSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2023Epsilon Spv III, L.P. first reported on Form ADV by Epsilon Health Investors, LLC (Venture Capital Fund), GAV $2,974,442Fund first reported on Form ADVFundsFactEpsilon Spv III, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2023Epsilon Spv I, L.P. first reported on Form ADV by Epsilon Health Investors, LLC (Venture Capital Fund), GAV $3,542,483Fund first reported on Form ADVFundsFactEpsilon Spv I, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Classification history
- Sep 14, 2026Syndicate platform (confirmed, 95%, cls-1)name or self-description says syndicate platform
- Sep 12, 2026Micro VC (confirmed, 95%, cls-1)venture manager, reported GAV $34.9M across 6 vehicles
- Sep 12, 2026Micro VC (confirmed, 95%, cls-1)venture manager, reported GAV $34.9M across 5 vehicles
Evidence
44 observations from 3 sources